NCT03831607View on ClinicalTrials.gov

A Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on HD

PHASE2CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

December 27, 2018

Primary Completion Date

November 26, 2019

Study Completion Date

November 26, 2019

Conditions
Hyperphosphatemia
Interventions
DRUG

KHK7791

KHK7791 30 mg, 20 mg ,10 mg or 5 mg tablets

Trial Locations (1)

Unknown

Study Site 1, Niigata

All Listed Sponsors
lead

Kyowa Kirin Co., Ltd.

INDUSTRY

NCT03831607 - A Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on HD | Biotech Hunter | Biotech Hunter